

Managing children with COVID-19 in a primary care setting

Shidan Tosif, MBBS FRACP PhD
Respiratory Infection Clinic Lead
Paediatrician, Royal Children's Hospital Melbourne
Research Fellow, Murdoch Children's Research Institute



COVID-19: Australian Children



Australia (all settings) :

- 23,500 children < 19 years
- 22% of all COVID-19 in Australia


Victoria :

- 8000 cases to date, 2981 active


2020 Victorian Experience:

- 3,261 cases (16% of all Victorian cases)
- 131 presented to ED: 115 (88%) required no medical intervention
- 51 admitted: most brief/precautionary
- 3 PICU (2 PIMS-TS, 1 CHD + severe COVID-19)

Source: NINDSS data 24/9/2021



Source: NINDSS data 24/9/2021



COVID-19 in Children




Delta strain

- ≠ more severe disease
 - Higher transmissibility
 - Numbers of cases overall and proportionate severe disease will be greater.
- Hospitalization rates 0.1 – 2%
 - Death <0.03%
- USA
 - 5.5m cases among 75 million children, with 480 deaths
 - Mortality rate of Covid-19 in children has decreased from 0.06% in 2020, to 0.01% 2021
 - UK
 - 470,000 infections (Feb 2020 - March 2021 pre-Delta), 25 deaths
 - Mar '21 - Sept '21, 52 deaths, no increase in the death rate overall
- MCRI Research Brief, <https://www.mcri.edu.au/sites/default/files/media/documents/covid-19-and-child-and-adolescent-health-140921.pdf>

COVID-19 Symptoms in Children

- Fever, cough, sore throat, rhinorrhea are most common symptoms
- Asymptomatic range from 14.6% to 42%
- Median illness duration - older children (7 days, IQR 3–12), younger children (5 days, 2–9)



Spectrum of Disease



- Acute Respiratory Tract Infection
 - Respiratory distress
 - Bronchiolitis, croup, pneumonia

- Medical complications
 - MIS-C/PIMS-TS (<0.1%)
 - Fever (≥ 3 days), signs of shock, rash and abdominal pain 2-6 weeks post COVID-19
 - Long COVID (4 - 66% *limitations)
 - Prolonged symptoms > 3 months rare
 - PE/DVT

• [Zimmerman et al \(2021\),
https://journals.lww.com/pidj/Abstract/9000/How_Common_Is_Long_COVID_in_Children_and_05677](https://journals.lww.com/pidj/Abstract/9000/How_Common_Is_Long_COVID_in_Children_and_05677)

Risk Factors for Severe Disease



- Older children > 12 years of age
- Unvaccinated
- Pre-existing comorbidities:
 - cancer, obesity, chronic respiratory/kidney/cardiovascular/neurological disorders, immune disorders/metabolic/hematologic disorders
 - Severe COVID-19: 5.1% of those with comorbidities, and in 0.2% without
 - *Risk of severe disease/death is still low in children with comorbidities*
- Children living with disadvantage, low socioeconomic or “minority” ethnic status

SEVERE ILLNESS

- Respiratory distress or visible work of breathing and unable to measure oxygen saturations
- Requiring Oxygen/NG/ IV fluids
 - Abnormal vital signs
 - Altered conscious state
- Febrile neonate <28 days
- Symptoms of Kawasaki's disease or PIMS-TS

Refer to local ED for assessment

0.5 %

HIGH RISK (with mild symptoms)

1. Complex medical, cardiac, respiratory or neurodevelopmental comorbidities
2. Immunosuppressed
3. Extreme obesity
4. Afebrile neonates (<28 days corrected)

Consider Paediatric Hospital in the Home admission after medical review, if additional monitoring required (refer below)

3-10%

MODERATE ILLNESS

1. Decreased oral intake/ hydration concerns
2. Mild -mod work of breathing with SaO2 >94%

LOW RISK

1. Asymptomatic or Mild Disease
2. Comorbidities but asymptomatic

GP led care: COVID-19 Positive Pathway

90-97%



COVID-19 Positive Pathway

Primary Care Management



- **Treat the clinical syndrome**
 - Most will be mild viral respiratory infections
 - Escalate if moderate/severe respiratory disease or symptomatic with significant comorbidities
- **Red flags**
 - Fever/rash/abdominal pain/shock (PIMS-TS)
 - Signs of thromboembolism
- **Consider alternate/co-existing diagnosis in child who has positive test for SARS-CoV-2 (e.g. sepsis)**

Hospital Treatment:

- Respiratory support
- Corticosteroids, if ongoing supplemental oxygen
- Corticosteroids/IVIG – PIMS-TS
- Venous thromboembolism prophylaxis

COVID-19 Indirect Impact



- **Indirect impact**
 - Wellbeing, anxiety
 - Education gap – disproportionate impact on disadvantaged, disengagement from education
 - Disruption of support for students with disabilities, mental health issues
 - Adverse impact on vulnerable children eg. free meal services, child protection
 - Social impact
 - **Social risk factors**
 - Social isolation
 - Risk of violence, abuse and neglect
 - Other child in home with significant disability, dev, behavioural or mental health problem
- **Parents may be admitted leaving children without alternative carers**
 - Parent / carer at high risk or in hospital
 - Children with complex medical needs (Tracheostomy/home ventilation, TPN etc.) likely to need hospital care if carers unwell
 - **Identify during intake whether there are care arrangements available if parents hospitalised**

Thank You

Shidan.Tosif@rch.org.au



Acknowledgements

The Royal Children's Hospital

- Hospital in the Home
- General Medicine

Monash Childrens Hospital

- Sarah Jame, Hospital in the Home

SAEFVIC

A/Prof Nigel Crawford

Research Team

- Alissa McMinn
- Belle Overmars
- Jill Nguyen
- Kate Dohle



References



- RCH CPGs
 - COVID-19:
https://www.rch.org.au/clinicalguide/guideline_index/COVID-19/
 - COVID-19 Positive Pathways:
https://www.rch.org.au/clinicalguide/guideline_index/Victorian_pathways_for_COVID-19_positive_children/

- Research Summary:
 - <https://www.mcri.edu.au/covid-19/research-briefs>